TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01307644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Web-based only (WO) weight intervention
Description: The WO intervention included evidence-based lifestyle modification for healthy eating and activity, with self-monitoring and goal setting, and messages based on constructs from the Health Promotion Model across 3 phases. The intent of the phases was to deliver more intensive intervention during Phase 1, transitioning to less intensive intervention during phase 2, to providing support for self managed weight maintenance during Phase 3.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Web-based only (WO) weight intervention
Description: The WO intervention included evidence-based lifestyle modification for healthy eating and activity, with self-monitoring and goal setting, and messages based on constructs from the Health Promotion Model across 3 phases. The intent of the phases was to deliver more intensive intervention during Phase 1, transitioning to less intensive intervention during phase 2, to providing support for self managed weight maintenance during Phase 3.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Web-based only (WO) weight intervention
Description: The WO intervention included evidence-based lifestyle modification for healthy eating and activity, with self-monitoring and goal setting, and messages based on constructs from the Health Promotion Model across 3 phases. The intent of the phases was to deliver more intensive intervention during Phase 1, transitioning to less intensive intervention during phase 2, to providing support for self managed weight maintenance during Phase 3.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: WO plus peer-led discussion board (WD)
Description: Includes WO intervention plus asynchronous discussion board managed by peer leader, whose identity is masked. The peer leader who posted theme-based messages, called primers, that were consistent with WO themes across phases.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: WO & professional email counseling (WE)
Description: Includes WO intervention plus professional email counseling provided by a registered dietitian whose identity is masked. The email counselor is responsible for reviewing eating, activity, weight logs, and goals on the web-site and send e-mail feedback, in addition to responding to email questions. The e-mail process will follow the 5A's Model for Behavioral Counseling (assess, advise, agree, assist, and arrange) that was adapted for this study.
Study: NCT02236117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: Will be included 160 children, 80 in an experimental group and 80 in a control group of both genders. The experimental group will realize aerobic training during 10 weeks (3×40min week-1; intensity, \>80% maximal aerobic velocity - MAV), while the control group will have involved with the physical education classes two times a week for 50 minutes each class. The aerobic protocol will be composed by 2 sessions of intermittent running and 1 session by continuous.
Study: NCT01510769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad
Description: Tablets, 400 mg once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad
Description: Tablets, 200 mg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Placebo QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: 80 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Febuxostat
Description: 80 mg
Study: NCT02230917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01866085

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AdVance® sling procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ARGUS Sling procedure
Study: NCT05306808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy class
Description: The supervised 1-hour group exercise class will be conducted twice a week, with a maximum of 8 patients in each class. Subjects will be given a home log for exercise recording. If subjects are unable to attend exercise class for any reason (eg., low counts or feeling unwell, etc.), they will be advised to continue xercises at home. On the day of one of the exercise classes each week, there will be an additional 1-hour group education/ discussion session which may be conducted by PT, OT, APN, dietician or medical social worker. Topics covered will include physical activity, management of fatigue, lymphoedema, neuropathy, brain fog, return to work, stress, nutrition, sexuality, psychosocial and caregiver issues. There will be 10 sessions of educational class in total for each subject.
Study: NCT00924859

Intervention type: OTHER
Intervention: ELISA Test
Description: assess the overall accuracy of D-dimer values and FXIII activation peptide (FXIII-AP), using a newly developed ELISA test
Study: NCT02659748

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk Fat
Description: Three daily servings of whole yogurt (3.25% fat).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control Fat
Description: Three daily servings of fat-free yogurt supplemented with a control fat.
Study: NCT01119079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: 10ml Normal Saline instilled in the epidural space

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Administration of epidural anesthesia for labor
Description: Standard procedure
Study: NCT03113136

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low wattage E cigarette device
Description: The low wattage E cigarette device will be provided to the participant and they will be instructed to vape ad libitum for 12 weeks and then be assessed at 6 months and 12 months for continued use of device.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High wattage E cigarette device
Description: The high wattage E cigarette device will be provided to the participant and they will be instructed to vape ad libitum for 12 weeks and then be assessed at 6 months and 12 months for continued use of device.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual brand cigarette
Description: The usual brand of cigarettes will be provided to the participant and they will be instructed to smoke ad libitum for the duration of the study.
Study: NCT00749047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 15-45 mg/day
Study: NCT00003497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
Study: NCT03069105

Intervention type: OTHER
Intervention: Questionnaire
Description: Participants will complete paper and pencil or electronic questionnaires at the cancer center or in the privacy of their own homes.
Study: NCT04306796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printed splints
Description: 3D printed made to measure splints

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermoplastic splints
Description: thermoplastic splints individually adjusted by occupational therapists
Study: NCT03564704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be added in Pre-phase Regimen, Induction-Regimen, Consolidation-Module of PDT-ALL-LBL protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Vincristine will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: IDA will be added to Induction-Regimen and Consolidation-Module of PDT-ALL-LBL protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: PEG-ASP will be added to Induction-Regimen and Consolidation-Module of PDT-ALL-LBL protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: Adriamycin will be added to Consolidation-Module of PDT-ALL-LBL protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be added to Consolidation-Module of PDT-ALL-LBL protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine.
Description: Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: VP-16 will be added to Consolidation-Module of PDT-ALL-LBL protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: AraC will be added to Consolidation-Module of PDT-ALL-LBL protocol.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration
Description: Bone marrow aspiration and additional tests will be performed in all module of PDT-ALL-LBL protocol.
Study: NCT01480297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: Salsalate 3 grams daily (1 gram TID with meals)
Study: NCT03126760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar Gel
Description: Acthar Gel 1 mL (80U) for subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for subcutaneous injection
Study: NCT01535365

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heat
Description: Application of heat pack to the back or neck sprain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold
Description: Application of ice pack to the back or neck sprain.
Study: NCT02326870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoLap
Study: NCT01951469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib and Pemetrexed/platinum
Description: Gefitinib 250mg is Taken Orally on day 1-28,combined Pemetrexed (D1)+cisplatin (D1-3) or Pemetrexed (D1) + nedaplatin (D1) chemotherapy, every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib mono-therapy
Description: Gefitinib 250mg is Taken Orally everyday
Study: NCT03556930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AlignRT system (VisionRT LTD, UK)
Description: Pediatric patient will watch age-proper movie during radiation treatment. The motion of pediatric patient will continually be monitored by an AlignRT system (VisionRT LTD, UK). Both movie and radiation beam will be paused if the motion of pediatric patient is beyond positioning accuracy threshold. Movie and beam will be resumed if pediatric patient is positioning with in tolerance.
Study: NCT01008280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: baclofen
Description: baclofen 10 mg tid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo pill tid
Study: NCT01363986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab [Herceptin]
Description: Initial loading dose of 4 mg/kg i.v. infusion, followed by weekly doses of 2 mg/kg for up to 18 weeks.
Study: NCT01780610

Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole and human chorionic gonadotrophin
Description: the follicular development is supported by Letrozole(LE) 2.5mg,once daily is introduced on cycle day 3 .And on cycle day 10 , a Vagina ultrasound is introduced to monitor the development of the follicular ,following by intramuscular gonadotrophin 37.5\~75 IU/d until there is a Luteinizing Hormone(LH) surge or ovulation .On the day appearing Luteinizing Hormone surge，patients is always introduced intramuscular human chorionic gonadotrophin(HCG) 10000 IU.If there is sill no Luteinizing Hormone surge when the follicle is 20-24mm ,the ovulation will be induced by HCG.Then the luteum was supported by HCG 2000-2500 IU/3d.Transfer of thawed embryos will be performed 3 days after ovulation is observed.

Intervention type: DRUG
Group type: OTHER
Intervention: estradiol and progesterone
Description: oral estradiol, 2 mg, once daily, was introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness was greater than 7mm, progesterone 40-60 mg in oil was administered via intramuscular injection. Transfer of thawed embryos was performed 3 days later
Study: NCT00130832

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine, Live, Oral, Pentavalent
Description: Three doses of rotavirus vaccine, live, oral, pentavalent. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine, Live, Oral, Pentavalent
Description: Three doses of rotavirus vaccine, live, oral, pentavalent. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Oral Poliovirus Vaccine (OPV)
Description: Three doses OPV. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Oral Poliovirus Vaccine (OPV) (staggered)
Description: Three doses OPV. Dose 1 was given 14 to 28 days post Dose 1 of RotaTeq, Dose 2 was given 14 to 28 days post Dose 2 of RotaTeq, and Dose 3 was given 14 to 28 days post Dose 3 of RotaTeq.
Study: NCT01207973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113823
Description: 5 dose-groups of multiple oral doses of BI 113823
Study: NCT02881268

Intervention type: OTHER
Intervention: blood sample

Intervention type: OTHER
Intervention: blood sample
Study: NCT03564704

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrathecal injection
Description: Intrathecal injection of chemotherapy will be performed in PDT-ALL-LBL protocol.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy will be performed for mediastinum and/or central nervous system leukemia/lymphoma in PDT-ALL-LBL protocol.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NGS
Description: Next-Generation-Sequencing (NGS) will be performed in PDT-ALL-LBL protocol.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Allo-HSCT will be added to LBL patients with available donor in PDT-ALL-LBL protocol.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Flow-MRD
Description: Flow-MRD will be added to PDT-ALL-LBL for bone marrow and cerebrospinal fluid samples.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FISH
Description: FISH will be added to PDT-ALL-LBL for bone marrow samples.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Flow immunophenotyping
Description: Flow immunophenotyping will be performed in PDT-ALL-LBL protocol.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Karyotyping
Description: Karyotyping will be performed in PDT-ALL-LBL protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: HDACi chidamide will be added to induction regimen, consolidation and maintenance module of PDT-ALL-LBL.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET-CT scan
Description: PET-scan will be performed for T-LBL patients for MRD assessment in PDT-ALL-LBL.
Study: NCT04357223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extract from Angelica archangelica leaf
Description: A standardized extract from Angelica archangelica leaf. Capsule, Twice Daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02585336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief intervention
Description: An interviewer provides health information, elicits motivation to reduce SSB consumption, and helps participants make implementation plans. Booster phone calls occur at 1 week after the intervention visit, and at 2 weeks and 24 weeks following the date on which SSBs sales ended at the participant's work location.
Study: NCT04345367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Description: Abrocitinib 200 mg administered as two 100 mg tablets to be taken orally once daily for 26 weeks. Placebo injections will be administered every other week for 24 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab 300 mg
Description: Dupilumab 300 mg administered as a single subcutaneous injection every other week for 24 weeks (2 injections on day 1). Placebo tablets will be administered daily.
Study: NCT02664571

Intervention type: DEVICE
Group type: OTHER
Intervention: Pet scan with FBB
Description: Patients will have a pet scan with Florbetaben (NEURACEQ : FBB). All other care corresponds to routine care.~Florbetaben is used during pet scans to visualize beta amyloid plaques and cannot be a separate intervention in and of itself.

Intervention type: DEVICE
Group type: OTHER
Intervention: Pet scan with FBB
Description: Patients will have a pet scan with Florbetaben (NEURACEQ : FBB). All other care corresponds to routine care.~Florbetaben is used during pet scans to visualize beta amyloid plaques and cannot be a separate intervention in and of itself.

Intervention type: DEVICE
Group type: OTHER
Intervention: Pet scan with FBB
Description: Patients will have a pet scan with Florbetaben (NEURACEQ : FBB). All other care corresponds to routine care.~Florbetaben is used during pet scans to visualize beta amyloid plaques and cannot be a separate intervention in and of itself.

Intervention type: DEVICE
Group type: OTHER
Intervention: Pet scan with FBB
Description: Patients will have a pet scan with Florbetaben (NEURACEQ : FBB). All other care corresponds to routine care.~Florbetaben is used during pet scans to visualize beta amyloid plaques and cannot be a separate intervention in and of itself.

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI scan
Description: Subjects will have an MRI scan at inclusion.

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI scan
Description: Subjects will have an MRI scan at inclusion.

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI scan
Description: Subjects will have an MRI scan at inclusion.

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI scan
Description: Subjects will have an MRI scan at inclusion.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: APO E genotyping
Description: Subjects will have APO (apolipoprotein) E genotyping if not already known.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: APO E genotyping
Description: Subjects will have APO (apolipoprotein) E genotyping if not already known.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: APO E genotyping
Description: Subjects will have APO (apolipoprotein) E genotyping if not already known.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: APO E genotyping
Description: Subjects will have APO (apolipoprotein) E genotyping if not already known.
Study: NCT01590758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical pexiganan cream 0.8%
Description: 14 days of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical placebo cream
Description: 14 days of treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard wound care
Description: 14 days of treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard wound care
Description: 14 days of treatment
Study: NCT03098615

Intervention type: DRUG
Group type: OTHER
Intervention: Jublia (Efinaconazole 10% Topical Solution)
Description: Efinaconazole 10% Topical Solution will be applied to the great toenail with the DLSO and dermatophytoma.
Study: NCT04334577

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: live attenuated zoster vaccine
Description: subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection
Study: NCT01041534

Intervention type: OTHER
Intervention: Survey
Description: Two surveys are sent to patients: Adjustable gastric band (AGB) Health Survey and a quality of life survey (EQ5D)
Study: NCT04408222

Intervention type: OTHER
Intervention: Awake proning
Description: Prone positioning of awake, as tolerated, for up to 24 hours daily.
Study: NCT01189019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 2mg intravitreal injection monthly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 2mg monthly x 3 doses, then as needed based on recurrence of activity on OCT
Study: NCT04314713

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scopolamine Hydrobromide Trihydrate
Description: Scopolamine Hydrobromide Trihydrate Intramuscular Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scopolamine Hydrobromide Trihydrate
Description: Scopolamine Hydrobromide Trihydrate Intramuscular Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scopolamine Hydrobromide Trihydrate
Description: Scopolamine Hydrobromide Trihydrate Intramuscular Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scopolamine Hydrobromide Trihydrate
Description: Scopolamine Hydrobromide Trihydrate Intramuscular Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scopolamine Hydrobromide Trihydrate
Description: Scopolamine Hydrobromide Trihydrate Intramuscular Injection
Study: NCT01324141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tempol
Description: Tempol gel will be applied to the bilateral groins and the gluteal cleft, avoiding a 3 cm radius from the anal verge, immediately prior to each fraction of radiation therapy (RT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU will be delivered as 1000mg/m(2)/day as 96 hour continuous infusion beginning on day 1 and 29.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin-C
Description: Mitomycin-C (MMC) will be delivered at a dose of 10mg/m(2) on days 1 and 29

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy (RT) will be delivered to a total dose of 50-54 Gray (Gy) based on tumor characteristics.
Study: NCT02862340

Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic test